Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738

Last updated date
Study Location
Pfizer Investigational Site
Jonesboro, Arkansas, 72401, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled
blood pressure, significant kidney disease.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Type 2 DiabetesEvaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00141232
  1. Irvine, Ayrshire
  2. Farnworth, Bolton
  3. Thornhill, Cardiff
  4. Fowey, Cornwall
  5. Launceston, Cornwall
  6. Penzance, Cornwall
  7. Penzance, Cornwall
  8. Saltash, Cornwall
  9. St Austell, Cornwall
  10. Darlington, County Durham
  11. Newton Aycliffe, County Durham
  12. Three Bridges, Crawley
  13. Plymouth, Devon
  14. Plymouth, Devon
  15. Bexhill on Sea, East Sussex
  16. Bexhill-On-Sea, East Sussex
  17. Bath, England
  18. Dronfield, Sheffield, England
  19. Surrey, England
  20. Halstead, Essex
  21. Stonehouse, Gloucestershire
  22. Southampton, Hampshire
  23. Hildenborough, Kent
  24. Thorneton-Clevely, Lancashire
  25. Balham, London
  26. Fulham, London
  27. Tooting, London
  28. Hayes, Middlesex
  29. Wellingborough, Northamptonshire
  30. Cookstown, Northern Ireland
  31. Frome, Somerset
  32. Fetcham, Surrey
  33. Woking, Surrey
  34. Crawley, West Sussex
  35. Leeds, West Yorkshire
  36. Bradford-on-Avon, Wiltshire
  37. Melksham, Wiltshire
  38. Swindon, Wiltshire
  39. Trowbridge, Wiltshire
  40. Warminster, Wiltshire
  41. Sheffield, Yorkshire
  42. Bath,
  43. Bath,
  44. Belfast,
  45. Birmingham,
  46. Bucks,
  47. Chesterfield,
  48. Chippenham, Wiltshire,
  49. Cornwall,
  50. County Antrim, Northern Ireland,
  51. Darlington,
  52. Dundee,
  53. Dundee,
  54. East Sussex,
  55. Isle of Wight,
  56. Isle of Wight,
  57. London,
  58. London,
  59. Westbury,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 2 DiabetesStudy Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
NCT01336738
  1. Jonesboro, Arkansas
  2. Jonesboro, Arkansas
  3. Los Angeles, California
  4. Palm Springs, California
  5. Jacksonville, Florida
  6. Melbourne, Florida
  7. West Palm Beach, Florida
  8. Conyers, Georgia
  9. Chicago, Illinois
  10. Louisville, Kentucky
  11. Fall River, Massachusetts
  12. Brooklyn, New York
  13. Cary, North Carolina
  14. Wilmington, North Carolina
  15. Columbus, Ohio
  16. East Providence, Rhode Island
  17. East Providence, Rhode Island
  18. Mount Pleasant, South Carolina
  19. Bristol, Tennessee
  20. Kingsport, Tennessee
  21. Dallas, Texas
  22. Houston, Texas
  23. Houston, Texas
  24. Houston, Texas
  25. San Antonio, Texas
  26. Charlottesville, Virginia
  27. Kenosha, Wisconsin
  28. Milwaukee, Wisconsin
  29. Winnipeg, Manitoba
  30. Strathroy, Ontario
  31. Thornhill, Ontario
  32. Toronto, Ontario
  33. Laval, Quebec
  34. St-Romuald, Quebec
  35. Budapest,
  36. Seoul,
  37. Seoul,
  38. Seoul,
  39. Guadalajara, Jalisco
  40. Guadalajara, Jalisco
  41. Monterrey, Nuevo Leon
  42. Bratislava,
  43. Tainan,
  44. Taipei,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
Official Title  ICMJE A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Brief Summary B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Diabetes, Type 2
Intervention  ICMJE
  • Drug: Placebo
    Tablets (n=6), 0 mg, once daily for 84 days
  • Drug: 150 mg PF-04991532
    Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
  • Drug: 450 mg PF-04991532
    Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
  • Drug: 750 mg PF-04991532
    Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
  • Drug: Sitagliptin 100 mg
    Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Matching placebo for PF-04991532 and Sitagliptin
    Intervention: Drug: Placebo
  • Experimental: 150 mg PF-04991532
    Intervention: Drug: 150 mg PF-04991532
  • Experimental: 450 mg PF-04991532
    Intervention: Drug: 450 mg PF-04991532
  • Experimental: 750 mg PF-04991532
    Intervention: Drug: 750 mg PF-04991532
  • Active Comparator: Sitagliptin 100 mg
    Intervention: Drug: Sitagliptin 100 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 5, 2013)
266
Original Estimated Enrollment  ICMJE
 (submitted: April 14, 2011)
240
Actual Study Completion Date  ICMJE March 2012
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2

Exclusion Criteria:

Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Hungary,   Korea, Republic of,   Mexico,   Slovakia,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01336738
Other Study ID Numbers  ICMJE B2611002
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP